Letters
Molnupiravir’s premature authorisation
Molnupiravir’s authorisation should be re-evaluated after the Panoramic trial is reported
BMJ 2022; 377 doi: https://doi.org/10.1136/bmj.o973 (Published 26 April 2022) Cite this as: BMJ 2022;377:o973
- Andrew Hill, senior visiting research fellow
- Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GF, UK
- andrewhillmv{at}gmail.com
Brophy’s editorial on Merck’s Move-Out trial of molnupiravir raises important concerns about the approval of molnupiravir to treat outpatients with covid-19 in the United Kingdom.1 Molnupiravir has not yet been approved in Europe,2 and orders were recently cancelled in France.3
Molnupiravir reduced the risk of hospital admission or death by 52% versus placebo in the interim analysis but raised risk by 35% among patients subsequently evaluated.4 There was no clear explanation …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.